Incyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript
Incyte Corporation misses on earnings expectations. Reported EPS is $0.746 EPS, expectations were $0.88.
Incyte Corp (INCY)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 36,179,665 | $2,061,155,515 | +1% | 25.85% |
| 2. | Armistice Capital Steven Boyd | 2,187,181 | $124,603,702 | +827% | 1.65% |
| 3. | GLG Partners Noam Gottesman | 2,098,656 | $119,560,432 | -12% | 0.3% |
| 4. | AQR Capital Management Cliff Asness | 1,560,717 | $88,914,053 | +32% | 0.15% |
| 5. | D E Shaw D. E. Shaw | 1,385,593 | $78,937,233 | -8% | 0.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $73.31 | 175,795 | Large Shareholder, Director | 33,419,055 | 2022-03-10 | Filing | |
| $73.31 | 14,490 | Large Shareholder, Director | 2,941,147 | 2022-03-10 | Filing | |
| $71.95 | 1,017 | Large Shareholder, Director | 33,243,260 | 2022-03-10 | Filing | |
| $71.95 | 84 | Large Shareholder, Director | 2,926,657 | 2022-03-10 | Filing | |
| $71.90 | 25,107 | Large Shareholder, Director | 33,242,243 | 2022-03-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $60.00 | 19,164 | Officer | 66,377 | 2024-06-12 | Filing | |
| $58.91 | 1,093 | Officer | 21,634 | 2024-06-06 | Filing | |
| $65.51 | 7,365 | Officer | 90,218 | 2024-01-03 | Filing | |
| $65.00 | 657 | Officer | 43,412 | 2024-01-02 | Filing | |
| $62.37 | 1,067 | Officer | 23,436 | 2023-12-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 24,298,022 | $1,525,672,802 | 0.03% | |
| 2. | 22,519,381 | $1,413,991,932 | 0.03% | |
| 3. | 10,120,170 | $635,445,474 | 0.03% | |
| 4. | 4,273,448 | $267,633,567 | 0.02% | |
| 5. | 3,355,698 | $210,704,387 | 0.01% |
News See All
12 Best S&P 500 Stocks To Buy According to Analysts
In this piece, we will take a look at the 12 best S&P 500 stocks to buy according to analysts.
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
5 Biotech Stocks with Huge Potential
In this article, we will take a look at the 5 biotech stocks with huge potential.
Incyte Corporation (NASDAQ:INCY) Q4 2023 Earnings Call Transcript
Incyte Corporation misses on earnings expectations. Reported EPS is $1.06 EPS, expectations were $1.21.
12 Most Promising Gene Editing Stocks According to Hedge Funds
In this piece, we will take a look at the 12 most promising gene editing stocks according to hedge funds.
13 Most Promising Healthcare Stocks According to Analysts
In this article, we discuss the 13 most promising healthcare stocks according to analysts.
Wall Street Analysts Just Trimmed Price Targets for These 5 Stocks
In this article, we discuss the 5 stocks receiving price-target cut from analysts.
5 Best Debt Free Stocks To Buy
Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutics for hematology and oncology.
Jim Simons Stock Portfolio: 12 Biggest Healthcare Stocks
In this piece, we will take a look at the 12 biggest healthcare stocks in Jim Simons' stock portfolio.
Billionaire Hedge Funds
